Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in IntangiblesChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcadia Biosciences (RKDA) Cash from Investing Activities (2016 - 2025)

Arcadia Biosciences filings provide 12 years of Cash from Investing Activities readings, the most recent being $250000.0 for Q2 2025.

  • On a quarterly basis, Cash from Investing Activities fell 94.62% to $250000.0 in Q2 2025 year-over-year; TTM through Dec 2025 was $750000.0, a 89.78% decrease, with the full-year FY2025 number at $750000.0, down 89.78% from a year prior.
  • Cash from Investing Activities hit $250000.0 in Q2 2025 for Arcadia Biosciences, down from $500000.0 in the prior quarter.
  • In the past five years, Cash from Investing Activities ranged from a high of $17.4 million in Q2 2021 to a low of -$4.7 million in Q2 2023.
  • Median Cash from Investing Activities over the past 5 years was $215000.0 (2024), compared with a mean of $1.2 million.
  • Biggest five-year swings in Cash from Investing Activities: plummeted 9925.0% in 2023 and later skyrocketed 12400.0% in 2025.
  • Arcadia Biosciences' Cash from Investing Activities stood at -$70000.0 in 2021, then soared by 501.43% to $281000.0 in 2022, then plummeted by 81.49% to $52000.0 in 2023, then surged by 4736.54% to $2.5 million in 2024, then crashed by 90.06% to $250000.0 in 2025.
  • The last three reported values for Cash from Investing Activities were $250000.0 (Q2 2025), $500000.0 (Q1 2025), and $2.5 million (Q4 2024) per Business Quant data.